Literature DB >> 1656441

Demonstration of a 1,25-dihydroxyvitamin D3-responsive protein in human lymphocytes: immunologic crossreactivity and inverse regulation with the vitamin D receptor.

X P Yu1, F G Hustmyer, W T Garvey, S C Manolagas.   

Abstract

Using Western blot analysis with a monoclonal antibody recognizing a 17-amino acid epitope of the 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]receptor, we have detected two crossreacting proteins in activated normal human lymphocytes. The smaller of the two proteins (50 kDa) was indistinguishable from the classical 1,25(OH)2D3 receptor and, similar to the classical 1,25(OH)2D3 receptor, was upregulated in a dose-dependent fashion by 1,25(OH)2D3. The larger crossreacting protein exhibited an electrophoretic mobility of 80 kDa, was localized in the cell cytosol, and appeared to be specific for activated lymphocytes since it was not detected in several other human cells including monocytes. More strikingly, the 80-kDa protein was downregulated in a dose-dependent fashion by 1,25(OH)2D3; this effect was independent of the mode of lymphocyte activation and specific for the 1,25(OH)2D3 metabolite of vitamin D3. However, two potent immunosuppressive agents, glucocorticoids and cyclosporin A, also inhibited the 80-kDa protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656441      PMCID: PMC52505          DOI: 10.1073/pnas.88.19.8347

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells.

Authors:  J M Lemire; J S Adams; R Sakai; S C Jordan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

3.  Monoclonal antibodies to chick intestinal receptors for 1,25-dihydroxyvitamin D3. Interaction and effects of binding on receptor function.

Authors:  J W Pike
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

4.  A simplification of the protein assay method of Lowry et al. which is more generally applicable.

Authors:  G L Peterson
Journal:  Anal Biochem       Date:  1977-12       Impact factor: 3.365

5.  1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes.

Authors:  H Reichel; H P Koeffler; A Tobler; A W Norman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production.

Authors:  D M Provvedini; C D Tsoukas; L J Deftos; S C Manolagas
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

7.  1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone.

Authors:  C D Tsoukas; D M Provvedini; S C Manolagas
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

8.  Vitamin D receptor expression in human lymphocytes. Signal requirements and characterization by western blots and DNA sequencing.

Authors:  X P Yu; H Mocharla; F G Hustmyer; S C Manolagas
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

9.  1,25-dihydroxyvitamin D3 receptors in human leukocytes.

Authors:  D M Provvedini; C D Tsoukas; L J Deftos; S C Manolagas
Journal:  Science       Date:  1983-09-16       Impact factor: 47.728

10.  Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation.

Authors:  A K Bhalla; E P Amento; T L Clemens; M F Holick; S M Krane
Journal:  J Clin Endocrinol Metab       Date:  1983-12       Impact factor: 5.958

View more
  8 in total

1.  Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population.

Authors:  B Halmos; F Szalay; T Cserniczky; E Nemesanszky; P Lakatos; S Barlage; G Schmitz; L Romics; A Csaszar
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

2.  Risk factors for vitamin D deficiency in sickle cell disease.

Authors:  Jin Han; Xu Zhang; Santosh L Saraf; Michel Gowhari; Robert E Molokie; Johara Hassan; Shivi Jain; Binal N Shah; Taimur Abbasi; Roberto F Machado; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

3.  Effects of 1 alpha,25-dihydroxy-vitamin D3 and calcipotriol on organotypic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs.

Authors:  A Limat; T Hunziker; L R Braathen
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption.

Authors:  X Q Li; V Tembe; G M Horwitz; D A Bushinsky; M J Favus
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

5.  Signal-dependent pleiotropic regulation of lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3: potent modulation of the hormonal effects by phorbol esters.

Authors:  F G Hustmyer; G Girasole; S C Manolagas
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

6.  Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma.

Authors:  Christoph Renné; Alexander H Benz; Martin L Hansmann
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

7.  Vitamin D up-regulates the vitamin D receptor by protecting it from proteasomal degradation in human CD4+ T cells.

Authors:  Martin Kongsbak; Marina R von Essen; Lasse Boding; Trine B Levring; Peter Schjerling; Jens P H Lauritsen; Anders Woetmann; Niels Ødum; Charlotte M Bonefeld; Carsten Geisler
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

8.  Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.

Authors:  Janice García-Quiroz; Rocío García-Becerra; David Barrera; Nancy Santos; Euclides Avila; David Ordaz-Rosado; Mariana Rivas-Suárez; Ali Halhali; Pamela Rodríguez; Armando Gamboa-Domínguez; Heriberto Medina-Franco; Javier Camacho; Fernando Larrea; Lorenza Díaz
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.